Chemotherapy might help cancer vaccines work

May 16, 2008

Chemotherapy given in conjunction with cancer vaccines may boost the immune system’s response, potentially improving the effectiveness of this promising type of cancer therapy, according to a study by researchers in the Duke Comprehensive Cancer Center.

“Chemotherapy first knocks out T regulatory cells that suppress immune function and we speculated that this might have a complementary effect when used in conjunction with vaccines, which work by boosting immune function,” said Timothy Clay, Ph.D., a researcher at Duke and a lead investigator on this study. “We tested this theory both pre-clinically and in patients who were part of a vaccine trial at Duke for gastrointestinal cancers, and found that our hypothesis seemed to be true.”

The researchers will present their findings at the annual American Society of Clinical Oncology meeting in Chicago, on May 31. The study was funded by the National Cancer Institute.

Researchers used a drug called denileukin diftitox (ONTAK) for this study; the drug is routinely used to treat a type of lymphoma and is known to deplete certain types of immune cells including the T regulatory cells that “put the brakes” on immune function. They speculated it might facilitate better immune responses to a cancer vaccine.

“In the lab work, we definitely saw a heightened immune response when we used the denileukin diftitox in conjunction with the vaccine. The vaccine we used targets a protein found in gastrointestinal tumors and works by boosting immune response to the cells carrying that protein,” Clay said. “From there, we gave the drug to 15 patients in a phase I study using the vaccine.”

The researchers found that when multiple doses of the denileukin diftitox were given, immune response to the vaccine was enhanced in these patients.

“This is encouraging. The next step will be to develop better drugs that support vaccines by enhancing the immune response they depend on to work,” Clay said. “It’s a concept that can be applied to any type of solid tumor, which has huge implications for cancer research.”

Vaccines are being used in clinical trials across the country to treat many malignancies, including lung cancer, brain tumors and colorectal cancer.

Source: Duke University Medical Center

Explore further: Enzyme that silences DNA activity may be crucially involved in health and cancer

add to favorites email to friend print save as pdf

Related Stories

Cloaked DNA nanodevices survive pilot mission

22 hours ago

It's a familiar trope in science fiction: In enemy territory, activate your cloaking device. And real-world viruses use similar tactics to make themselves invisible to the immune system. Now scientists at ...

The promise and peril of nanotechnology

Mar 26, 2014

Scientists at Northwestern University have found a way to detect metastatic breast cancer by arranging strands of DNA into spherical shapes and using them to cover a tiny particle of gold, creating a "nano-flare" ...

Research team implants human innate immune cells in mice

Mar 18, 2014

(Phys.org) —Overcoming a major limitation to the study of the origins and progress of human disease, Yale researchers report that they have transplanted human innate immune cells into mouse models, which ...

New nanoparticle that only attacks cervical cancer cells

Mar 17, 2014

One of the most promising technologies for the treatment of various cancers is nanotechnology, creating drugs that directly attack the cancer cells without damaging other tissues' development. The Laboratory ...

Recommended for you

User comments : 0

More news stories